BRIEF-AIGO Holding Announces US IPO Of 2 Million Shares-March 2024-www.financetom.com

BRIEF-AIGO Holding Announces US IPO Of 2 Million Shares

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-AIGO Holding Announces US IPO Of 2 Million Shares

Aug 21, 2025 3:21 PM

Aug 21 (Reuters) -

AIGO Holding:

* AIGO HOLDING LTD - ANNOUNCES US IPO OF 2,000,000 SHARES -

SEC

FILING

* AIGO HOLDING LTD - ANTICIPATED IPO PRICE BETWEEN $4.00 AND

$6.00

PER SHARE - SEC FILING

* AIGO HOLDING LTD - INTENDS TO LIST SHARES ON NASDAQ UNDER

SYMBOL

'AIGO' - SEC FILING

* AIGO HOLDING : EDDID SECURITIES USA INC IS UNDERWRITER TO

IPO-

SEC FILING

Source text:

Previous page： Innovate Extends Subscription Period of Rights Offering Next page： Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Innovate Extends Subscription Period of Rights Offering

Mar 25, 2024

05:57 PM EDT, 03/25/2024 (MT Newswires) -- Innovate (VATE) said Monday its board extended the subscription period for its rights offering to April 9. Certain shareholders and noteholders as of record on March 6 are eligible to participate in the rights offering, according to the company. Innovate shares were up 2.2% in after-hours activity. Price: 0.71, Change: +0.02, Percent Change:...

Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours

Mar 25, 2024

05:54 PM EDT, 03/25/2024 (MT Newswires) -- Eledon Pharmaceuticals ( ELDN ) said late Monday the 12th participant has been enrolled in an ongoing phase 2 trial evaluating its lead investigational product tegoprubart head-to-head with tacrolimus to prevent organ rejection in kidney transplantation. Organ rejection is a major cause of graft failure in transplantation procedures, according to the company. Eledon...

Market Chatter: Cleveland-Cliffs Made Sure Deal with US Steel Was Clear of Antitrust Issues

Mar 25, 2024

05:51 PM EDT, 03/25/2024 (MT Newswires) -- Cleveland-Cliffs ( CLF ) discussed potential ways with the US government to structure a potential merger with United States Steel ( X ) to avoid antitrust issues, Cleveland-Cliffs ( CLF ) Chief Executive Lourenco Goncalves told Bloomberg Monday. Goncalves said in an interview with the news outlet that he wanted to make sure...

Couchbase Insider Sold Shares Worth $521,858, According to a Recent SEC Filing

Mar 25, 2024

05:57 PM EDT, 03/25/2024 (MT Newswires) -- Gregory N Henry, Senior Vice President & Chief Financial Officer, on March 21, 2024, sold 18,747 shares in Couchbase ( BASE ) for $521,858. Following the Form 4 filing with the SEC, Henry has control over a total of 442,846 shares of the company, with 112,194 shares held directly and 330,652 controlled indirectly....